A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting
Open Access
- 9 July 2012
- journal article
- Published by Springer Science and Business Media LLC in BMC Health Services Research
- Vol. 12 (1), 192
- https://doi.org/10.1186/1472-6963-12-192
Abstract
Background: Patients undergoing major orthopaedic surgery (MOS), such as total hip (THR) or total knee replacement (TKR), are at high risk of developing venous thromboembolism (VTE). For thromboembolism prophylaxis, the oral anticoagulant rivaroxaban has recently been included in the German diagnosis related group (DRG) system. However, the cost-effectiveness of rivaroxaban is still unclear from both the German statutory health insurance (SHI) and the German hospital perspective. Objectives: To assess the cost-effectiveness of rivaroxaban from the German statutory health insurance (SHI) perspective and to analyse financial incentives from the German hospital perspective. Methods: Based on data from the RECORD trials and German cost data, a decision tree was built. The model was run for two settings (THR and TKR) and two perspectives (SHI and hospital) per setting. Results: Prophylaxis with rivaroxaban reduces VTE events (0.02 events per person treated after TKR; 0.007 after THR) compared with enoxaparin. From the SHI perspective, prophylaxis with rivaroxaban after TKR is cost saving (€27.3 saving per patient treated). However, the cost-effectiveness after THR (€17.8 cost per person) remains unclear because of stochastic uncertainty. From the hospital perspective, for given DRGs, the hospital profit will decrease through the use of rivaroxaban by €20.6 (TKR) and €31.8 (THR) per case respectively. Conclusions: Based on our findings, including rivaroxaban for reimbursement in the German DRG system seems reasonable. Yet, adequate incentives for German hospitals to use rivaroxaban are still lacking.Keywords
This publication has 33 references indexed in Scilit:
- Is there adequate provision of venous thrombo-embolism prophylaxis following hip arthroplasty? An audit and international surveyThe Annals of The Royal College of Surgeons of England, 2010
- Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in CanadaThrombosis and Haemostasis, 2010
- A Cost-Effectiveness Model Comparing Rivaroxaban and Dabigatran Etexilate with Enoxaparin Sodium as Thromboprophylaxis after Total Hip and Total Knee Replacement in the Irish Healthcare SettingPharmacoEconomics, 2009
- Comparing methodologies for the cost estimation of hospital servicesThe European Journal of Health Economics, 2008
- Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgeryJournal of Thrombosis and Haemostasis, 2007
- Rivaroxaban (BAY 59‐7939) – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxenBritish Journal of Clinical Pharmacology, 2006
- Estimated Annual Costs of Prophylaxis and Treatment of Venous Thromboembolic Events Associated With Major Orthopedic Surgery in FranceClinical and Applied Thrombosis/hemostasis, 2006
- Incidence of post-thrombotic syndrome in patients with previous pulmonary embolismThrombosis and Haemostasis, 2004
- Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosisThe Lancet, 1992
- Low-Molecular-Weight HeparinThe New England Journal of Medicine, 1986